Documents
Application Sponsors
NDA 215430 | AXSOME THERAPEUTICS, INC. | |
Marketing Status
Application Products
001 | TABLET, EXTENDED RELEASE;ORAL | 45MG/105MG | 0 | AUVELITY | DEXTROMETHORPHAN HYDROBROMIDE AND BUPROPION HYDROCHLORIDE |
FDA Submissions
TYPE 3/4; Type 3 - New Dosage Form and Type 4 - New Combination | ORIG | 1 | AP | 2022-08-18 | PRIORITY |
Submissions Property Types
CDER Filings
AXSOME THERAPEUTICS, INC.
cder:Array
(
[0] => Array
(
[ApplNo] => 215430
[companyName] => AXSOME THERAPEUTICS, INC.
[docInserts] => ["Medication Guide","https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/215430Orig1s000Correctedlbl.pdf#page=25"]
[products] => [{"drugName":"AUVELITY","activeIngredients":"DEXTROMETHORPHAN HYDROBROMIDE AND BUPROPION HYDROCHLORIDE","strength":"45MG\/105MG","dosageForm":"TABLET, EXTENDED RELEASE;ORAL","marketingStatus":"Prescription","te":"None","rld":"No","rs":"No"}]
[labels] => [{"actionDate":"08\/18\/2022","submission":"ORIG-1","supplementCategories":"Approval","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2022\\\/215430Orig1s000Correctedlbl.pdf\"}]","notes":""}]
[originalApprovals] => [{"actionDate":"08\/18\/2022","submission":"ORIG-1","actionType":"Approval","submissionClassification":"Type 3 - New Dosage Form and Type 4 - New Combination","reviewPriority":"PRIORITY","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2022\\\/215430Orig1s000Correctedlbl.pdf\"},{\"name\":\"Letter (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/appletter\\\/2022\\\/215430Orig1s000Correctedltr.pdf\"}]","notes":">"}]
[supplements] =>
[actionDate] => 2022-08-18
)
)